Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Policy / Regulatory

NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Company Deals

Sansure Biotech to Acquire Sinobioway Hygene for $110M to Boost Product Pipeline

Fineline Cube Jan 14, 2025

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced plans to acquire 100%...

Company Drug

Novo Nordisk Launches Rybelsus in China, World’s First Oral GLP-1RA

Fineline Cube Jan 14, 2025

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the commercial launch of its innovative...

Company Drug

Merck’s Keytruda Gains NMPA Approval for HNSCC Indication in China

Fineline Cube Jan 14, 2025

US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) has announced that it has received...

Company Drug

Huadong Medicine Gets FDA Nod for Phase I Study of HDM2006 in Solid Tumors

Fineline Cube Jan 14, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Company Deals Drug

Zhaoke Ophthalmology Partners with AFT for Brimochol PF Distribution in ANZ

Fineline Cube Jan 14, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced a strategic distribution and supply agreement with...

Company Drug

Tonghua Dongbao Begins Phase II Trial for GLP-1/GIP Agonist THDBH120 in Weight Loss

Fineline Cube Jan 14, 2025

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has announced a significant milestone in its clinical development...

Company Deals

Neo Modulus Secures $40.9M Series C Funding for Regenerative Medical Devices

Fineline Cube Jan 14, 2025

Neo Modulus (Suzhou) Medical Sci-Tech Co., Ltd., a prominent developer of regenerative implantable medical devices...

Company Deals

MediLink Therapeutics and AstraZeneca Collaborate on YL201 and Imfinzi Combo for Solid Tumors

Fineline Cube Jan 14, 2025

Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced a clinical cooperation agreement with...

Company Deals

Simcere Zaiming and AbbVie Ink $1.055B License Deal for MM Drug SIM0500

Fineline Cube Jan 14, 2025

China-based Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced a significant strategic move through its...

Company Drug

CSPC’s Prusogliptin Approved in China for Type 2 Diabetes Treatment

Fineline Cube Jan 14, 2025

China’s National Medical Products Administration (NMPA) has granted marketing approval to CSPC Pharmaceutical Group Co.,...

Company Deals

3SBio Acquires Licensing Rights to Duality Biologics’ HER2-Targeting ADC DB-1303

Fineline Cube Jan 14, 2025

China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a...

Company Deals Medical Device

CBC Group’s R-Bridge Healthcare Fund Boosts Mirxes with $40M for Cancer Detection Expansion

Fineline Cube Jan 14, 2025

CBC Group’s R-Bridge Healthcare Fund has made a significant investment of USD 40 million in...

Company Drug

JW Therapeutics’ Carteyva Granted Breakthrough Therapy Designation by CDE

Fineline Cube Jan 13, 2025

China-based JW Therapeutics (HKG: 2126) has announced that its Carteyva (relmacabtagene autoleucel injection) has been...

Company Drug

CSPC Pharmaceutical’s ADC Pipeline Advances with SYS 6041 Approval

Fineline Cube Jan 13, 2025

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has reported significant progress in its antibody...

Company Deals

Suzhou Ribo and Boehringer Ingelheim Reach Pre-Clinical Milestone in NASH/MASH Partnership

Fineline Cube Jan 13, 2025

China-based Suzhou Ribo Life Science Co., Ltd has announced the achievement of a first pre-clinical...

Company Medical Device

Johnson & Johnson MedTech’s Dual Energy Catheter Gains CE Mark

Fineline Cube Jan 13, 2025

US major Johnson & Johnson MedTech has announced that its Dual Energy THERMOCOOL SMARTTOUCH SF...

Company Drug

Henlius Biotech Gains NMPA Clearance for HLX43 ADC Study

Fineline Cube Jan 13, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that it has received clearance from...

Company Deals

Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development

Fineline Cube Jan 13, 2025

China-based Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070) has entered into a licensing deal...

Company Deals Drug

Gilead Sciences and LEO Pharma Alliance Targets Inflammatory Diseases

Fineline Cube Jan 13, 2025

US-based major Gilead Sciences Inc. (NASDAQ: GILD) has formed a strategic alliance with Denmark-based dermatology...

Company Drug

Junshi Biosciences’ Mindewei Receives Full Approval in China

Fineline Cube Jan 13, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the conditional...

Posts pagination

1 … 273 274 275 … 711

Recent updates

  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
  • Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201
  • InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth
  • NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Company

InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.